title: HIV-1 gp160 envelope protein modulates proliferation and apoptosis in mesangial cells.
abstract: Mesangial cell (MC) hyperplasia and accumulation of extracellular matrix are the predominant features of HIV-associated nephropathy (HIVAN). Since mice transgenic for HIV-1 genes show renal lesions mimicking HIVAN, we studied the effect of HIV-1 gp160 protein on cultured murine MC (MMC) proliferation and apoptosis. HIV-1 gp160 protein stimulated (p < 0.001) MMC proliferation when compared with control MMCs. This effect of gp160 protein peaked at a concentration of 0.01 microg/ml. MMCs treated with a higher concentration of gp160 protein (0.1 microg/ml) or for a prolonged period of time (72 h) showed apoptosis rather than cell proliferation. These studies were further confirmed by DNA fragmentation and end labeling assays. gp160 also enhanced apoptosis in human MCs. Tumor necrosis factor (TNF)-alpha enhanced (p < 0.001) MMC apoptosis, and anti-TNF-alpha antibodies inhibited gp160-induced MMC apoptosis. In addition, gp160 protein attenuated MMC expression of Bcl-2 mRNA expression. These results suggest that gp160-induced apoptosis may be affected in part by the release of TNF-alpha and associated with attenuated mRNA expression of Bcl-2 by MMCs.
authors.affiliation: Department of Medicine, Long Island Jewish Medical Center, and Long Island Campus for Albert Einstein College of Medicine, New York, NY 11040, USA.
authors.forename: P C
authors.initials: PC
authors.lastname: Singhal
authors.forename: P
authors.initials: P
authors.lastname: Sharma
authors.forename: K
authors.initials: K
authors.lastname: Reddy
authors.forename: V
authors.initials: V
authors.lastname: Sanwal
authors.forename: J
authors.initials: J
authors.lastname: Rawal
authors.forename: N
authors.initials: N
authors.lastname: Gibbons
authors.forename: N
authors.initials: N
authors.lastname: Franki
mesh_terms: D016263:AIDS-Associated Nephropathy / Q000209:etiology / Q000473:pathology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001973:Bromodeoxyuridine / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis; D053938:DNA Fragmentation / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects; D015683:Gene Products, gag / Q000633:toxicity; D019254:Genes, bcl-2 / Q000187:drug effects; D005920:Glomerular Mesangium / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D019302:HIV Envelope Protein gp160 / Q000633:toxicity*; D015497:HIV-1 / Q000472:pathogenicity*; D006801:Humans; D007700:Kinetics; D051379:Mice; D009500:Neutralization Tests; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000494:pharmacology
chemical_list: D015683:Gene Products, gag; D019302:HIV Envelope Protein gp160; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D004247:DNA; D001973:Bromodeoxyuridine